Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

NCT01938248

Last updated date
Study Location
Cardiovascular Associates of Mesa, PC
Mesa, Arizona, 85206, United States
Contact
905-527-4322

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

905-527-4322

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atrial Fibrillation, Stroke
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor capable of detecting SCAF

2. At least one episode of SCAF ≥ 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter. SCAF requires electrogram confirmation (at least one episode) unless ≥ 6 hours in duration.

3. Age ≥ 55 years

4. Risk Factor(s) for Stroke:

Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors

Other risk factors are:

- hypertension

- CHF

- diabetes

- vascular disease (i.e. CAD, PAD or Aortic Plaque)

- female

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry,
Holter) lasting ≥ 6 minutes, with or without clinical symptoms


2. Mechanical valve prosthesis, deep vein thrombosis, recent pulmonary embolism or other
condition requiring treatment with an anticoagulant


3. Contra-indication to apixaban or aspirin:


1. Allergy to aspirin or apixaban


2. Severe renal insufficiency (creatinine clearance must be calculated in all
patients; any patient with either a serum creatinine > 2.5 mg/dL [221 µmol/L] or
a calculated creatinine clearance < 25 ml/min is excluded)


3. Serious bleeding in the last 6 months or at high risk of bleeding (this includes,
but is not limited to: prior intracranial hemorrhage, active peptic ulcer
disease, platelet count < 50,000/mm3 or hemoglobin < 10 g/dL, recent stroke
within past 10 days, documented hemorrhagic tendencies or blood dyscrasias)


4. Moderate to severe hepatic impairment


5. Ongoing need for combination therapy with aspirin and clopidogrel (or other
combination of two platelet inhibitors)


6. Meets criteria for requiring lower dose of apixaban AND also has ongoing need for
strong inhibitors of CYP 3A4 or P-glycoprotein (e.g., ketoconazole, itraconazole,
ritonavir or clarithromycin)


7. Ongoing need for strong dual inducers of CYP 3A4 or P-glycoprotein (e.g.,
rifampin, carbamazepine, phenytoin, St. John's wort)


4. Received an investigational drug in the past 30 days


5. Participants considered by the investigator to be unsuitable for the study for any of
the following reasons:


1. Not agreeable for treatment with either aspirin or apixaban or anticipated to
have poor compliance on study drug treatment


2. Unwilling to attend study follow-up visits


3. Life expectancy less than the expected duration of the trial2 years due to
concomitant disease


6. Women who are pregnant, breast-feeding or of child-bearing potential without an
acceptable form of contraception in place (sterilization, hormonal contraceptives,
intrauterine device, barrier methods or abstinence)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Atrial Fibrillation, StrokeApixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
NCT01938248
  1. Mesa, Arizona
  2. Little Rock, Arkansas
  3. Aurora, Colorado
  4. Naples, Florida
  5. Pensacola, Florida
  6. Owensboro, Kentucky
  7. Boston, Massachusetts
  8. Lansing, Michigan
  9. Ypsilanti, Michigan
  10. Columbia, Missouri
  11. Saint Louis, Missouri
  12. Kalispell, Montana
  13. Camden, New Jersey
  14. Hackensack, New Jersey
  15. Ridgewood, New Jersey
  16. Albany, New York
  17. Charlotte, North Carolina
  18. Raleigh, North Carolina
  19. Cleveland, Ohio
  20. Hershey, Pennsylvania
  21. Lancaster, Pennsylvania
  22. Falls Church, Virginia
  23. Mainz, Rheinland-Pfalz
  24. Chemnitz, Saxony
  25. Dresden, Saxony
  26. Gottingen,
  27. Tuebingen,
  28. Vimercate, Monza Brianza MB
  29. Nola, Napoli
  30. Ancona,
  31. Bologna,
  32. Bologna,
  33. Bolzano,
  34. Trieste,
  35. Dorchester, Dorset
  36. Basingstoke, Hampshire
  37. Portsmouth, Hampshire
  38. Paisley, Renfrewshire
  39. Shropshire, West Midlands
  40. Blackpool,
  41. Glasgow,
  42. Liverpool,
  43. Newcastle-upon-Tyne,
  44. Montreal, Quebec
  45. Ede,
  46. Brussels,
  47. Kortrijk,
  48. Rotterdam, Zuid-Holland
  49. Madrid,
  50. Ottawa, Ontario
  51. Roeselare,
  52. Huelva,
  53. Vancouver, British Columbia
  54. Montreal, Quebec
  55. Liege,
  56. Emmen,
  57. Drammen, Buskerud
  58. Aarhus,
  59. Laval, Quebec
  60. Victoria, British Columbia
  61. Oslo,
  62. Hamburg,
  63. Barcelona,
  64. Valladolid,
  65. Viborg,
  66. Pamplona,
  67. Yvoir,
  68. Toronto, Ontario
  69. Budapest,
  70. Roosendaal,
  71. A Coruna,
  72. Heerenveen, Friesland
  73. Liège,
  74. Aabenraa,
  75. Alicante,
  76. Marbella,
  77. Gilly,
  78. Budapest,
  79. Edmonton, Alberta
  80. Breda, Noord-Brabant
  81. Aalst,
  82. Oakville, Ontario
  83. Prague,
  84. Geneva,
  85. Edmonton, Alberta
  86. Santiago De Composte, A Coruna
  87. Trois-Rivières, Quebec
  88. Halifax, Nova Scotia
  89. Montreal, Quebec
  90. Zutphen, Gelderland
  91. San Fermo Della Batt, Como
  92. Rome,
  93. Valencia,
  94. Arlon,
  95. Hilleroed, North Zealand
  96. Fribourg,
  97. Heerlen, Limburg
  98. Newmarket, Ontario
  99. Deventer,
  100. Lausanne, Vaud
  101. Toronto, Ontario
  102. St. Gallen, Saint Gallen
  103. London, Ontario
  104. Tilburg,
  105. Hellerup,
  106. Hamilton, Ontario
  107. Arnhem,
  108. Aalborg,
  109. Calgary, Alberta
  110. Balatonfured, Veszprem
  111. Homburg/Saar, Saarland
  112. Hoogeveen,
  113. Montreal, Quebec
  114. Veldhoven,
  115. Madrid,
  116. Sherbrooke, Quebec
  117. Frankfurt, Hesse
  118. Goes,
  119. Winnepeg, Manitoba
  120. Modena,
  121. Majadahonda,
  122. Lorca, Murcia
  123. Amsterdam,
  124. Kitchener, Ontario
  125. Edmonton, Alberta
  126. Odense,
  127. Basel, Basel-Stadt
  128. Leuven,
ALL GENDERS
55 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Official Title  ICMJE Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Brief Summary This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk factors for stroke.
Detailed Description

Device-detected sub-clinical atrial fibrillation (SCAF) is a new disorder that has been recognized since the availability of implantable devices capable of long term continuous heart rhythm monitoring. It is characterized by one or more runs of rapid atrial arrhythmia detected by the device without symptoms and without any clinical atrial fibrillation (AF) detected by the usual methods, (i.e. electrocardiogram, Holter monitor, etc.). In the ASSERT trial, SCAF was detected by a pacemaker or implantable cardioverter defibrillator (ICD) in nearly 40% of patients during 2 and a half years of follow up. The presence of SCAF increased stroke risk by 2.5-fold (1). The risk of stroke or systemic embolism among patients with SCAF and a CHADS2 score ? 4 was 2.75% per year. Oral anticoagulation is effective and safe for stroke prevention in patients with clinical atrial fibrillation, but it is unknown if the same risk benefit ratio exists for anticoagulation therapy in patients with SCAF (2;3). SCAF differs from clinical AF in being of shorter duration, being asymptomatic, and often have a more regular rhythm in the right atrium where it is typically detected. Data ASSERT suggest that the increase in stroke risk with SCAF may be less than the increase with clinical AF. Therefore opinion leaders have written that the role of oral anticoagulation for the treatment of SCAF is uncertain and that randomized trials of anticoagulation are needed (4;5). Recent surveys of pacemaker clinic practice indicate that only 25% of patients with SCAF are treated with oral anticoagulation (6;7). Thus there is clinical equipoise for a trial of oral anticoagulation compared to aspirin in higher risk patients with SCAF.

Apixaban is a Factor Xa inhibitor that is an effective and safe anticoagulant. It has been shown to have an excellent risk benefit profile for stroke prevention in clinical AF (14, 15). It is highly suitable to test if oral anticoagulation therapy will reduce the risk of stroke or systemic embolism in SCAF.

Patients will be randomized double-blind to receive apixaban or aspirin. Apixaban dose will be 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ? 60 kg or serum creatinine ? 133 mmol/L). Those assigned to aspirin will receive a dose of 81 mg daily. The study will be event driven and will continue until 248 patients have experienced a primary outcome event.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE
  • Atrial Fibrillation
  • Stroke
Intervention  ICMJE
  • Drug: Apixaban
    apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ? 60 kg or serum creatinine ? 133 mmol/L)
    Other Name: Eliquis
  • Drug: aspirin
    aspirin 81 mg once daily
    Other Names:
    • ASA
    • acetylsalicylic acid
Study Arms  ICMJE
  • Active Comparator: Control
    Aspirin 81 mg once daily
    Intervention: Drug: aspirin
  • Experimental: Intervention
    Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ? 60 kg or serum creatinine ? 133 mmol/L)
    Intervention: Drug: Apixaban
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 4, 2013)
4000
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date August 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor capable of detecting SCAF
  2. At least one episode of SCAF ? 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter. SCAF requires electrogram confirmation (at least one episode) unless ? 6 hours in duration.
  3. Age ? 55 years
  4. Risk Factor(s) for Stroke:

Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors

Other risk factors are:

  • hypertension
  • CHF
  • diabetes
  • vascular disease (i.e. CAD, PAD or Aortic Plaque)
  • female

Exclusion Criteria:

  1. Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter) lasting ? 6 minutes, with or without clinical symptoms
  2. Mechanical valve prosthesis, deep vein thrombosis, recent pulmonary embolism or other condition requiring treatment with an anticoagulant
  3. Contra-indication to apixaban or aspirin:

    1. Allergy to aspirin or apixaban
    2. Severe renal insufficiency (creatinine clearance must be calculated in all patients; any patient with either a serum creatinine > 2.5 mg/dL [221 µmol/L] or a calculated creatinine clearance < 25 ml/min is excluded)
    3. Serious bleeding in the last 6 months or at high risk of bleeding (this includes, but is not limited to: prior intracranial hemorrhage, active peptic ulcer disease, platelet count < 50,000/mm3 or hemoglobin < 10 g/dL, recent stroke within past 10 days, documented hemorrhagic tendencies or blood dyscrasias)
    4. Moderate to severe hepatic impairment
    5. Ongoing need for combination therapy with aspirin and clopidogrel (or other combination of two platelet inhibitors)
    6. Meets criteria for requiring lower dose of apixaban AND also has ongoing need for strong inhibitors of CYP 3A4 or P-glycoprotein (e.g., ketoconazole, itraconazole, ritonavir or clarithromycin)
    7. Ongoing need for strong dual inducers of CYP 3A4 or P-glycoprotein (e.g., rifampin, carbamazepine, phenytoin, St. John's wort)
  4. Received an investigational drug in the past 30 days
  5. Participants considered by the investigator to be unsuitable for the study for any of the following reasons:

    1. Not agreeable for treatment with either aspirin or apixaban or anticipated to have poor compliance on study drug treatment
    2. Unwilling to attend study follow-up visits
    3. Life expectancy less than the expected duration of the trial2 years due to concomitant disease
  6. Women who are pregnant, breast-feeding or of child-bearing potential without an acceptable form of contraception in place (sterilization, hormonal contraceptives, intrauterine device, barrier methods or abstinence)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Kim Simek905-527-4322 ext 40524[email protected]
Contact: Heather Beresh905-527-4322 ext 40351[email protected]
Listed Location Countries  ICMJE Belgium,   Canada,   Czechia,   Denmark,   Germany,   Hungary,   Italy,   Netherlands,   Norway,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01938248
Other Study ID Numbers  ICMJE ARTESiA
2014-001397-33 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Jeff Healey, Population Health Research Institute
Study Sponsor  ICMJE Population Health Research Institute
Collaborators  ICMJE
  • Bristol-Myers Squibb
  • Pfizer
  • Medtronic
  • Canadian Institutes of Health Research (CIHR)
Investigators  ICMJE
Principal Investigator:Jeff Healey, M.D.Population Health Research Institute
Study Chair:Stuart Connolly, M.D.Population Health Research Institute
Principal Investigator:Marco Alings, M.D.Working Group Cardiovascular Research Netherlands
Principal Investigator:Renato Lopes, M.D.Duke Clinical Research Institute
PRS Account Population Health Research Institute
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP